CD274 and hepatocellular carcinoma: A prospective, single-arm, phase 2 study of TACE combined with anti-PD-L1 antibody (envafolimab) and lenvatinib in unresectable HCC demonstrated promising survival outcomes and operable conversion rates with a tolerable safety profile (140).